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INTRODUCTION
Acute graft-versus-host disease (GVHD) is a signiﬁcant
cause of morbidity and mortality after allogeneic hemato-
poietic stem cell transplantation (HSCT). The effectiveness
of steroids as front-line therapy was primarily assessed in the
1980s, and response rates of about 50% were reported [1-6].
However, since then, the nature of HSC donors has dramat-
ically changed with the frequent use of unrelated donor
(URD) HSC. In addition, different GVHD grading systems
have been developed with varying abilities to predict out-
comes after GVHD therapy.
To assess the impact of systemic steroids as initial ther-
apy for acute GVHD in the past decade, we retrospectively
analyzed the clinical response and survival of 443 HSCT
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ABSTRACT
Acute GVHD remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplan-
tation (HSCT). In a retrospective analysis, the response of 443 HSCT patients who received prednisone, 60 mg/m2,
for 14 days followed by an 8-week taper, as initial therapy for acute GVHD from 1990 through 1999 at a single
institution was examined. Median patient age was 29.0 years (range, 0.3-60.3 years), with 40% of patients <20 years
old. Patients received HSCT from 201 related (189 matched sibling/ 12 partially matched) and 242 unrelated (130
HLA-A, B, DRB1 matched/112 partially matched) donors. GVHD score was measured and outcomes compared
using the Minnesota, Consensus, and International Bone Marrow Transplant Registry (IBMTR) grading systems.
Prior to initiation of steroid therapy, severe (grades III-IV) acute GVHD was observed in 57 (13%) patients (Min-
nesota or Consensus grading) and in 192 (43%) patients (IBMTR grading). At day 28 of treatment, overall improve-
ment was observed in 55% of patients, with durable (≥28 days) complete response observed in 35% and partial
response observed in 20% of patients. Patients with acute lower gastrointestinal GVHD (± other organ involve-
ment) had lower response rates. In multivariate logistic regression analysis, recipients of related donor grafts and
recipients of GVHD prophylaxis other than methotrexate alone had the highest likelihood of overall response. Ini-
tial Minnesota GVHD grade or Consensus GVHD grade was not associated with significant differences in overall
response, whereas patients with an initial IBMTR grade of B or C had a higher likelihood of response. Chronic
GVHD developed in 42% of patients by 1 year after HSCT. The probability of survival at 1 year after initiation of
steroid therapy was 53% (95% confidence interval, 48%-58%). In Cox regression analysis, factors associated with
better survival included patients’ youth, receipt of related or HLA-matched unrelated grafts, and administration of
GVHD prophylaxis other than T-cell depletion in all 3 grading systems. Lower initial GVHD grade (I-II or A-B) led
to better survival. These data suggest that steroids provide an active but inadequate therapy for acute GVHD, espe-
cially with highergrade GVHD. More effective prophylaxis and therapy for acute GVHD is needed for mismatched
unrelated donor recipients and for those with severe GVHD.
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patients, uniformly treated at a single institution from 1990
through 1999 on a protocol of prednisone, 60 mg/m2 (or
methylprednisolone equivalent) for 14 days followed by an
8-week taper. Response to therapy was analyzed by taking
into account 3 different acute GVHD grading methods, the
Minnesota [3,7], Consensus [7], and International Bone
Marrow Transplant Registry (IBMTR) [8] grading systems.
PATIENTS AND METHODS
Patients
Clinical and laboratory data were retrieved from the
University of Minnesota Blood and Marrow Transplant
(BMT) Database, which systematically and prospectively
collects data on all consecutive patients undergoing trans-
plantation at our institution. Patients were eligible for the
study if they developed within 120 days after HSCT grades
II to IV acute GVHD as deﬁned by the Minnesota criteria.
Patients with limited (grade I) skin acute GVHD were eligi-
ble if there was progression of disease within 7 days or no
improvement after 10 days of topical steroid therapy. From
January 1990 to December 1999, 1181 patients received an
allogeneic HSCT at the University of Minnesota. All trans-
plantation and GVHD protocols were reviewed and approved
by the Institutional Review Board. All patients and/or
guardians gave informed consent. Of these 1181 patients,
741 (63%) developed acute GVHD, of which 443 (60%)
received systemic steroid therapy as initial therapy and were
enrolled in this study.
Patient characteristics, including underlying disease,
type of donor, and GVHD prophylaxis, are shown in Table 1.
Patients received their HSCT from January 1990 to
December 1999 and were followed for a median of 3.9 years
(range, 1.0-9.4 years). HSC sources included bone marrow
(BM, n = 378), peripheral blood stem cells (PBSC, n = 39),
and umbilical cord blood (UCB, n = 26). Details of the
preparative therapy and GVHD prophylaxis, as well as sup-
portive therapy techniques, have been previously reported
[9-16]. Eighty-eight percent of patients received a total
body irradiation (TBI)-based regimen, and 12% of patients
received a chemotherapy-alone regimen. GVHD prophy-
laxis consisted of cyclosporin A (CSA)-based therapy in 74%
of patients, T-cell depletion in 16% of patients, methotrex-
ate (MTX) alone in 7% of patients, and tacrolimus-based
therapy in 3% of patients.
Diagnosis, Staging, and Grading of GVHD
Acute GVHD was diagnosed clinically with histological
conﬁrmation whenever possible. Symptoms of acute GVHD
were graded by 3 separate grading systems, Minnesota,
Consensus, and IBMTR (Table 2). The Minnesota system
was derived from standard clinical criteria modified to
include upper gastrointestinal (GI) acute GVHD [3,7]. The
Consensus grading system [7] and the IBMTR severity
index [8] were also used. The Minnesota and Consensus sys-
tems are similar except for the liver and lower GI staging
criteria for grades III and IV GVHD. The IBMTR index is
the most different and tends to give a higher GVHD score
for a given combination of GVHD stages.
Table 1. Clinical Features of Patients with Acute GVHD (N = 443)
Features No. of Patients (%)
Age
<20 y 175 (40)
20-39 y 152 (34)
≥40 y 116 (26)
Median (range), y 29 (0.3-60)
Year of Transplantation
1990-1992 82 (18)
1993-1995 181 (41)
1996-1999 180 (41)
Male:Female Ratio 266:177 (3:2)
Male recipient/male donor 157 (35)
Male recipient/female donor 107 (24)
Female recipient/male donor 80 (18)
Female recipient/female donor 97 (22)
Male recipient/unknown donor 2 (1)
Diagnosis
Acute lymphoblastic leukemia 75 (17)
Acute myelogenous leukemia 91 (20)
Chronic myelogenous leukemia 139 (31)
Myelodysplastic syndrome 36 (8)
Other leukemias 4 (1)
Other malignancy 17 (4)
Metabolic disorder 34 (8)
Aplastic anemia/bone marrow failure 26 (6)
Immunodeficiency 21 (5)
Donor type
Matched related 189 (43)
Mismatched related 12 (3)
Matched unrelated 130 (29)
Mismatched unrelated 112 (25)
Preparative therapy
Cyclophosphamide and TBI 338 (76)
Other chemotherapy and TBI 54 (12)
Chemotherapy alone 51 (12)
GVHD prophylaxis
CSA containing 329 (74)
MTX containing (no CSA) 29 (7)
T-cell depletion 70 (16)
Tacrolimus 15 (3)
Table 2. Acute GVHD Grading Systems
Grade* Skin† Liver GI Upper GI
Minnesota [3,7]
I 1-2 0 0 0
II 3 1 1 1
III — 2-4 2-3
IV 4 — 4
Consensus [7]
I 1-2 0 0 0
II 3 1 1 1
III — 2-3 2-4
IV 4 4 —
IBMTR [8]‡
A 1 0 0 0
B 2 1-2 1-2 1
C 3 3 3
D 4 4 4
*Each grade is based on maximum stage for each involved organ.
†Each column identiﬁes minimum stage for organ grade.
‡Modiﬁed as shown to include upper GI GVHD.
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Grade of GVHD refers to clinical (not histologic) grade
throughout this report. Initial score was calculated using the
maximum stage in each organ within a 10-day window (–5 to
+5 days) of initiation of steroid therapy. Real-time staging of
each organ was determined by the attending physician, sup-
ported by laboratory and clinical information abstracted
from the medical records. The overall grade was determined
by a computer algorithm incorporating all available clinical
GVHD organ staging data, centrally reviewed by the
GVHD Grading Committee at our center (S.M.D., D.J.W.)
and prospectively recorded in the University of Minnesota
BMT Database. To make the IBMTR grading comparable
to Minnesota and the Consensus grading, we assigned an
IBMTR B index value to patients who had initial upper GI
acute GVHD with a IBMTR score of grade B or lower.
GVHD Therapy
All patients received a daily thrice-divided dose of pred-
nisone 60 mg/m2 by mouth (PO) (or methylprednisolone
intravenous equivalent, 48 mg/m2) for 7 consecutive days,
then a daily single dose of prednisone for 7 days as initial
therapy for acute GVHD. Patients were maintained on
therapeutic levels of CSA in 329 patients (74%) or tacrolimus
in 15 patients (3%). Additionally, patients with acute skin
GVHD were treated with topical 0.1% triamcinolone cream
or 1% hydrocortisone cream (for facial rash) 3 times daily. If
a complete response to prednisone was observed, patients
continued therapy with single-dose prednisone 60 mg/m2
per day PO for a total of 14 days and then commenced a
taper of steroids over 8 weeks [17].
Patients received supportive care that included ongoing
prophylaxis for bacterial infections (250 mg penicillin VK
[penicillin V potassium] PO, twice a day) and fungal infec-
tions (clotrimazole, nystatin, or fluconazole), pneumocystis
carinii pneumonia (trimethoprim-sulfa double strength
twice daily every Monday and Tuesday), and cytomegalo-
virus (CMV) (800 mg acyclovir PO 5 times per day). Children
received the same prophylaxis appropriately dose-adjusted
for weight.
Measurement of GVHD Response to Prednisone
Response to therapy was evaluated by the attending
physician and prospectively recorded in the University of
Minnesota BMT Database at treatment days 7, 14, 21, 28,
and 42 by determining the GVHD clinical stage score for
each time point (±3 days) [5]. The day 28 response was
determined from the maximum acute GVHD grade in each
organ observed 28 days (±14 days) after prednisone treat-
ment was initiated. Complete response (CR) was deﬁned as
the complete resolution of all acute GVHD symptomatology
in all organs. This score had to be maintained for 28 days
(ie, beyond day 56 after initiating prednisone therapy) with-
out additional treatment to be considered a CR. Partial
response (PR) was defined as durable (≥28 further days)
improvement in GVHD stage in all initial GVHD target
organs without complete resolution and without worsening
in any other GVHD target organs. No response (NR) was
defined as the same grade of GVHD or progression of
GVHD in any organ or death before day 28 after pred-
nisone initiation. Progression was defined as worsening
GVHD in ≥1 organ with or without amelioration in any
organ. Steroid-resistant acute GVHD was defined as pro-
gression of acute GVHD after 4 days of treatment with
prednisone or no improvement of acute GVHD after 7 days
of treatment with prednisone. Patients with steroid-resistant
GVHD were treated with secondary therapy.
For assessment of treatment response, a GVHD organ
stage score was determined for each patient, as previously
described [2]. This stage score represented the sum of each
acute GVHD organ stage (0-4) plus 1 point for upper GI
involvement and thus had a maximum possible score of 13.
Statistical Analysis
The major endpoints of this study were response to
GVHD therapy at day 28 after treatment and survival. Uni-
variate analysis of response to therapy was performed by Pear-
son’s chi-square test. The independent effect of study variables
on response was determined using logistic regression [18].
Survival was measured from the time of initiation of
therapy with prednisone. The Kaplan-Meier method was
used to estimate survival with 95% confidence intervals
derived from standard errors [19]. Comparison within study
cohorts was completed by the log-rank statistic. Cox regres-
sion was used to determine the independent effect of these
factors [20]. Cumulative incidence curves were calculated to
estimate the incidence of chronic GVHD and infectious
complications. Deaths from other causes were treated as
competing risks [21].
Study variables considered included age, year of trans-
plantation, sex, sex match, diagnosis, type of donor (related,
matched unrelated, mismatched unrelated), CMV serostatus
of the patient and donor, GVHD prophylaxis regimen, con-
ditioning regimen, initial grade of acute GVHD, time to
onset of acute GVHD, time to therapy, and type of organ
involvement. The effect of response to therapy on survival
was also investigated as a time-dependent covariate.
RESULTS
Maximum initial GVHD stage in each organ for each
patient is shown in Table 3. The GVHD grade at time of
initiation of steroid therapy is shown in Table 4. With both
the Minnesota and Consensus grading systems, the initial
GVHD grades were grade I in 122 patients (28%), grade II
in 264 patients (60%), grade III in 50 patients (11%), and
grade IV in 7 patients (2%). With the IBMTR severity
index, the initial GVHD grades were grade A in 83 patients
(19%), grade B in 168 patients (38%), grade C in 181 patients
(41%), and grade D in 11 patients (2%). Median time to
onset of GVHD from day of HSCT was 27 days (range,
Table 3. Maximum Initial GVHD Stage at the Onset of Prednisone Therapy*
0 1 2 3 4
Skin 87 (20%) 48 (11%) 136 (31%) 169 (37%) 3 (1%)
Liver 415 (94%) 9 (2%) 7 (1%) 8 (2%) 4 (1%)
Rectal 362 (82%) 46 (10%) 18 (4%) 13 (3%) 4 (1%)
Upper GI 335 (76%) 108 (24%)
*Maximum stage during window (–5 to +5 days) around initiation of
prednisone therapy.
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8-94 days). Median time to treatment with prednisone from
day of HSCT was 30 days (range, 8-94 days).
Of the 443 patients treated with prednisone, durable
response (CR + PR) was observed in 245 patients (55%) by day
28 after initiation of therapy. CR was achieved in 157 patients
(35%), PR in 88 patients (20%), and NR in 178 patients
(40%). Twenty patients (5%) were unevaluable because of early
death but were considered as treatment failures for the purpose
of analysis.
Various patient characteristics and transplantation condi-
tions were analyzed for their association with clinical
response to prednisone therapy by day 28. In univariate
analysis, factors associated with a statistically significant
higher likelihood of CR/PR included year of HSCT, type of
HSC donor, GVHD prophylaxis, and initial GVHD IBMTR
grade. CR/PR was achieved in 35 (43%) of 82 patients who
received transplants in 1990-1992, 101 (56%) of 181 patients
who received transplants in 1993-1995, and 109 (61%) of
180 patients who received transplants in 1996-1999 (P = .03).
CR/PR was observed in 118 (59%) of 201 related donor
recipients compared to that in 76 (58%) of 130 HLA-
matched URD recipients and 51 (46%) of 112 mismatched
URD recipients (P = .05). Only 9 (31%) of 29 patients given
MTX alone as GVHD prophylaxis achieved a response to
steroids compared to 188 (57%) of 329 patients given CSA-
containing GVHD prophylaxis, 38 (54%) of 70 recipients of
T-cell–depleted grafts, and 10 (67%) of 15 patients given
tacrolimus (P = .04). There was no association between
CR/PR following steroid treatment and patient age, sex, diag-
nosis, CMV serostatus, preparative therapy, time to onset of
GVHD, or time from diagnosis of GVHD to initiation of
systemic steroid therapy.
The response to steroid treatment among patients with
various combinations of organ involvement was analyzed.
The number of organs involved with acute GVHD was not
a prognostic indicator of response, as response was observed
in 91 (54%) of 170 patients with 1 organ involved with
GVHD, 82 (52%) of 157 patients with 2 organs involved,
and 72 (62%) of 116 patients with 3 or 4 organs involved
(P = .23). Patients with lower GI acute GHVD (± other
organ involvement) responded less often. Of the 81 patients
with lower GI involvement, 34 (42%) achieved CR/PR ver-
sus 211 (58%) of 362 patients without lower GI involvement
(P < .01). The only statistically significant combination of
organ involvement was that of lower GI and skin GVHD.
Twenty-one (42%) of 50 patients with lower GI and skin acute
GVHD obtained CR/PR versus 224 (57%) of 393 patients
without this combination (P = .04). Organ stage score was
not predictive of response to GVHD treatment.
The clinical factors relevant to the likelihood of achiev-
ing CR/PR were examined in a logistic regression analysis
using each GVHD grading system (Table 5). In each grad-
ing system, HLA-mismatched URD recipients were less
likely to respond to steroid therapy than were related donor
recipients or HLA-matched URD recipients. Additionally,
using each grading system, the use of MTX for GVHD pro-
phylaxis was associated with a lower probability of response
to steroids. There was a tendency toward lower response to
steroids with higher initial GVHD grade as scored by the
Minnesota and Consensus methods, although this was not
statistically significant (Figure 1). Surprisingly, using the
IBMTR index, patients with initial grade B or C GVHD
had a higher probability of responding to steroid therapy
than did patients with initial grade A GVHD. Patients with
Table 4. Initial Acute GVHD Grade
Grading Grade I Grade II Grade III Grade IV
System or A or B or C or D
Minnesota 122 (28%) 264 (60%) 50 (11%) 7 (2%)
Consensus 122 (28%) 264 (60%) 50 (11%) 7 (2%)
IBMTR 31 (7%) 220 (50%) 181 (41%) 11 (2%)
Table 5. Factors Associated with CR/PR in Acute GVHD: Logistic Regres-
sion Analysis
Grading System Relative Likelihood
and Variable of CR/PR (95% CI) P
Minnesota
Type of donor
Related 1.0
Matched unrelated 0.8 (0.5-1.4) .52
Mismatched unrelated 0.5 (0.3-0.8) <.01
GVHD prophylaxis
CSA 1.0
MTX 0.3 (0.1-0.6) <.01
T-cell depletion 0.9 (0.5-1.6) .77
Tacrolimus 1.2 (0.4-3.8) .63
Initial grade of GVHD
I 1.0
II 0.9 (0.6-1.5) .79
III 0.8 (0.4-1.7) .66
IV 0.3 (0.1-1.9) .23
Consensus
Type of donor
Related 1.0
Matched unrelated 0.8 (0.5-1.4) .47
Mismatched unrelated 0.5 (0.3-0.8) <.01
GVHD prophylaxis
CSA 1.0
MTX 0.3 (0.1-0.6) <.01
T-cell depletion 0.9 (0.5-1.6) .78
Tacrolimus 1.2 (0.4-3.8) .71
Initial grade of GVHD
I 1.0
II 0.9 (0.6-1.5) .78
III 0.8 (0.4-1.5) .47
IV 0.7 (0.2-3.5) .66
IBMTR
Type of donor
Related 1.0
Matched unrelated 1.0 (0.6-1.6) >.80
Mismatched unrelated 0.6 (0.3-1.0) .04
GVHD prophylaxis
CSA 1.0
MTX 0.2 (0.1-0.6) <.01
T-cell depletion 0.8 (0.5-1.4) .59
Tacrolimus 0.9 (0.3-2.9) >.80
Initial grade of GVHD
A 1.0
B 2.5 (1.2-5.3) .01
C 1.7 (0.8-3.6) .15
D 0.7 (0.1-3.1) .62
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IBMTR grade A GVHD (rash involving less than 25% of
body surface) had a lower probability of CR or PR than did
those with IBMTR grade B or C GVHD. The 31 patients
with initial IBMTR grade A GHVD were similar in age and
distribution of diagnoses to those with grade B or C (data
not shown). Additionally, the median number of days from
the time of GVHD diagnosis to initiation of steroid therapy
was similar (2 days for grade A patients [n = 31], 1 day
for grade B patients [n = 220], 1 day for grade C patients
[n = 181], and 4 days for grade D patients [n = 11]). Patients
with grade A GVHD had to attain complete resolution of
their stage I skin rash to achieve a PR or CR. Any residual
rash would constitute treatment failure. Age and year of
HSCT were not significant predictors of response to
steroids in the multiple regression analyses.
Chronic GVHD
One year after initiation of steroid therapy, 187 patients
had developed chronic GVHD, resulting in a cumulative
incidence of 42% (95% conﬁdence interval [CI], 37%-47%).
With the Minnesota grading system, chronic GVHD devel-
oped in 48 (39%) of the 122 patients (95% CI, 30%-48%)
with initial grade I GVHD, 117 (44%) of the 264 patients
(95% CI, 37%-51%) with initial grade II GVHD, 21 (42%)
of 50 patients with initial grade III GVHD (95% CI, 27%-
57%), and 1 (14%) of 7 patients with grade IV GVHD (95%
CI, 0%-34%; P = .39). In contrast, with the IBMTR grading
system, chronic GVHD developed in 15 (48%) of the
31 patients (95% CI, 28%-68%) with initial grade A GVHD,
93 (42%) of the 220 patients (95% CI, 35%-49%) with initial
grade B GVHD, 76 (42%) of 181 patients with initial grade
C GVHD (95% CI, 34%-50%), and 3 (27%) of 11 patients
with grade D GVHD (95% CI, 3%-51%; P = .76). Sixty-four
(41%) of 157 patients who had CR to steroids later developed
chronic GVHD (95% CI, 33%-49%), 42 (48%) of 88 who
had PR later developed chronic GVHD (95% CI, 36%-
60%), and 81 (46%) of 178 who had NR later developed
chronic GVHD (95% CI, 38%-54%; P < .01).
Infectious Complications
Within the ﬁrst 100 days after initiation of steroid ther-
apy for GVHD, 182 patients (41%) developed bacterial
infections (95% CI, 37%-45%), 14 patients (3%) developed
fungal infections (95% CI, 1%-5%), and 96 patients (22%)
developed CMV antigenemia (95% CI, 18%-26%). Only
1 patient developed posttransplantation lymphoproliferative
disease by day 100 after steroid therapy.
Survival
In the entire cohort of 443 patients, 234 were alive 1 year
after initiation of treatment, with a Kaplan-Meier estimate
of 53% (95% CI, 48%-58%) survival at 1 year. Various clin-
ical factors were examined for their association with
improved survival. The probability of survival 12 months
after administration of steroids was 58% (95% CI, 52%-
64%) in related donor recipients, 53% (95% CI, 45%-61%)
in HLA-matched URD recipients, and 44% (95% CI, 34%-
52%) in HLA-mismatched URD recipients (P = .05) (Fig-
ure 2). Recipients of T-cell–replete grafts had a higher
probability of survival at 1 year than did recipients of
T-cell–depleted grafts (55% [95% CI, 50%-60%] versus
40% [95% CI, 29%-51%]; P = .01). With each GVHD
grading system, a lower initial GVHD grade was associated
with a higher probability of survival (Figure 3). In addition,
a higher organ stage score was associated with a lower prob-
ability of 1-year survival (P < .01). Other clinical factors,
Figure 1. Initial acute GVHD grade and overall response to steroid therapy.
Figure 2. The effect of HSC donor type on survival 1 year after initia-
tion of steroid therapy.
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including age and sex of recipient, year of transplantation,
underlying diagnosis, preparative therapy, source of stem
cells (BM versus UCB versus PBSC), and CMV serostatus,
had no association with survival.
In Cox regression analysis, the use of a related donor or
HLA-matched unrelated graft, CSA as GVHD prophylaxis,
younger age at time of HSCT, and lower grade of initial
GVHD grade using each grading method were indepen-
dently associated with greater survival (Table 6).
Causes of Death
Fifty-four patients died within 1 year after initiation of
steroid therapy. The primary cause of death was GVHD in
48 patients (89%) and relapse in 6 patients (11%). Infections
were a contributing cause of death in 36 deaths (67%).
DISCUSSION
This study represents the largest series from a single
institution analyzing the effectiveness of steroid therapy as
initial therapy for acute GVHD in patients who received
HSCT in the 1990s. We observed a response to therapy in
55% of patients and a durable CR in 35% of patients. These
results are similar to those observed in the 2 largest previ-
ously reported series, primarily consisting of matched sib-
ling donor recipients who received transplants in the late
1970s and 1980s [1,2].
Few demographic or clinical factors were statistically
predictive of a response to steroid therapy of GVHD.
Related donor recipients and HLA-matched URD recipi-
ents had similar overall response rates (59% versus 58%)
and 1-year survival rates (58% and 53%). In contrast,
patients who received HLA-mismatched URD grafts
responded less frequently (46%), and their projected 1-year
survival rate (44%) was lower. This result differs from an
earlier study reported from our institution that showed a
poorer response to GVHD therapy in all URD recipients
[4]. In this earlier study, 42 patients with acute GVHD after
HLA-matched (29%) or HLA-mismatched (71%) URD
BMT from 1985 to 1990 were treated with a prednisone
Figure 3. Initial acute GVHD grade and probability of survival 1 year after initiation of steroid therapy.
Table 6. Clinical Factors Associated with 1-Year Mortality in Acute
GVHD: Multivariate Analysis
Grading System Relative Risk
and Factor of Death (95% CI) P
Minnesota
Type of donor
Related 1.0
Matched unrelated 1.3 (0.9-1.9) .10
Mismatched unrelated 1.8 (1.3-2.6) <.01
GVHD prophylaxis
Other* 1.0
T-cell depletion 1.4 (1.0-2.1) .04
Age, in decades 1.2 (1.1-1.3) <.01
Initial grade of GVHD
I-II 1.0
III-IV 1.5 (1.0-2.2) .05
Consensus
Type of donor
Related 1.0
Matched unrelated 1.3 (0.9-1.9) .10
Mismatched unrelated 1.8 (1.3-2.6) <.01
GHVD prophylaxis
Other* 1.0
T-cell depletion 1.4 (1.0-2.1) .04
Age, in decades 1.2 (1.1-1.3) <.01
Initial grade of GVHD
I-II 1.0
III-IV 1.5 (1.0-2.2) .05
IBMTR
Type of donor
Related 1.0
Matched unrelated 1.3 (0.9-1.8) .10
Mismatched unrelated 1.8 (1.2-2.5) <.01
GVHD prophylaxis
Other* 1.0
T-cell depletion 1.4 (1.0-2.1) .04
Age, in decades 1.1 (1.0-1.2) <.01
Initial grade of GVHD
A-B 1.0
C-D 1.4 (1.1-1.9) <.01
*CSA, MTX, and/or tacrolimus.
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regimen similar to that in the present study. Overall
response to steroids was observed in only 24% of patients
and CR in 21% of patients [4]. The improved response
rates to GVHD therapy in this present study may be due in
part to advancements in supportive care. These advance-
ments may also explain our ﬁnding of improved response to
therapy in patients undergoing transplantation in more
recent years.
The number of organs involved in GVHD was not pre-
dictive of response to therapy. Patients with lower GI
involvement, especially in combination with skin involve-
ment, responded less often. We have previously reported a
higher likelihood of response to steroids when GVHD is
limited to the GI tract [5]. In addition, we have previously
observed that liver and/or cutaneous GVHD involvement
were independent predictors of poor response [2].
Recipients of T-cell–replete grafts had a higher proba-
bility of survival at 1 year than did recipients of T-cell–
depleted grafts. A similar finding of improved survival
in recipients of T-cell–replete grafts was observed at our
institution in a recent analysis of the response to equine
antithymocyte globulin (ATG) for steroid-resistant acute
GVHD [22].
The IBMTR severity index was developed in 1997 as an
objective GVHD grading system [8] with the intent to
improve prognostic capabilities compared to the Glucksberg
system [23]. At the University of Minnesota, we use a modi-
ﬁed Glucksberg grading system that incorporates upper GI
GVHD [3,7]. The Minnesota and Consensus GVHD grad-
ing systems are similar except for the liver and lower GI
staging criteria for grades III and IV GVHD. The IBMTR
index is the most different and tends to give a higher
GVHD score for a given combination of GVHD stages,
resulting in a different distribution of initial GVHD scores.
In this study, a higher proportion of patients graded by the
IBMTR severity index were categorized as having severe
(grades C or D) GVHD (43%) than were patients graded
according to the Minnesota or Consensus systems (13%
with grades 3 or 4). Initial GVHD grade was not predictive
of response to prednisone therapy, except for patients with
IBMTR index B or C, who were more likely to achieve
overall improvement. With each grading system, severe
GVHD and poor response to therapy were associated with
lower probability of survival. The Minnesota and IBMTR
grading systems better discriminate between initial GVHD
grade and survival. Although no GVHD grading system
appears superior, the significant discrepancy in assigned
grade for a given stage(s) of GVHD is important to note,
especially when comparing outcomes of GVHD trials using
different GVHD grading systems.
Despite many advances in the past decade in the man-
agement of complications related to HSCT, treatment of
acute GVHD remains suboptimal. Although a subset of
patients may achieve a durable response with steroids, new
approaches to GVHD prophylaxis and treatment are
needed.
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